Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability

Core Points - Idorsia successfully raised CHF 65.6 million by offering 16.4 million new and treasury shares at a price of CHF 4.00 per share, which is aligned with the Volume-Weighted Average Price from the last 30 days [2][3] - The proceeds will be used to strengthen Idorsia's balance sheet, fund the commercial trajectory of QUVIVIQ, advance a science-driven pipeline, and for general corporate purposes [2][3] - The offering was oversubscribed, indicating strong demand from institutional investors and reflecting confidence in Idorsia's potential [3] Financial Details - The offering consisted of 12.9 million newly issued shares, representing 5.45% of the approximately 236 million shares listed on SIX prior to the transaction, and 3.5 million treasury shares [3] - The newly issued shares are expected to be listed on the SIX Swiss Exchange on October 13, 2025, with payment and settlement anticipated on October 14, 2025 [4] Lock-up Agreement - Idorsia has agreed to a 180-day lock-up period for the newly issued shares, which includes the equity line established in September 2025 [5] - Founding shareholders Jean-Paul and Martine Clozel will also adhere to a 180-day lock-up period after the listing of the new shares, subject to customary exceptions [5] Company Overview - Idorsia aims to challenge medical paradigms by discovering, developing, and commercializing transformative medicines, evolving into a leading biopharmaceutical company [6][7] - The company is headquartered near Basel, Switzerland, and focuses on small-molecule drugs that can change treatment paradigms for various patients [7][8]